Merck Sharp & Dohme has cut the price of Cozaar by up to a third in the UK, but denied the move was related to the OFT report on drug pricing.
The blockbuster hypertension treatment has been on the market for more than 10 years and is one of the most widely prescribed angiotensin II receptor blockers (ARB) in the UK.
ARBs were among a number of drug classes identified in the Office of Fair Trading's report on the PPRS earlier this year as being priced significantly out of line with patient benefits.
MSD announced the price cut shortly after the government responded to the OFT report - saying it would overhaul the current drug pricing system - but the company said the timing was purely coincidental.
Hmmmmmm!
More at Pharmafocus
No comments:
Post a Comment